The release of the Center for Medicare and Medicaid Services (CMS) average sales price (ASP) figures for the second quarter revealed a startling and dangerous trend for ranibizumab products: up to a 50% drop in pricing from the first quarter of 2025. As previously reported, Formycon AG’s marketing partner Sandoz has decided to take the … Continue reading The Implications of the Freefall in Ranibizumab ASPs